Журнал кардиореспираторных исследований 2026. №2/1
Subject of the article
FEATURES OF ATRIAL FIBRILLATION IN PATIENTS WITH ISCHEMIC HEART DISEASE COMBINED WITH THYROID PATHOLOGY (20-23)
Authors
Sh.A. Amirova
Institution
Master’s Resident in Cardiology Tashkent State Medical University
Abstract
Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia in patients with ischemic heart disease (IHD). Thyroid pathology significantly affects myocardial electrophysiological properties and increases the risk of arrhythmias. Purpose: To study the features of atrial fibrillation in patients with ischemic heart disease combined with thyroid pathology. Research materials and methods: A total of 120 patients aged 45–75 years with IHD were examined. The patients were divided into three groups: IHD without thyroid pathology (n=40), IHD with hyperthyroidism (n=40), and IHD with hypothyroidism (n=40). All patients underwent clinical examination, assessment of TSH, free T3 and T4 levels, electrocardiography, and 24-hour Holter monitoring. The prevalence and forms of atrial fibrillation were evaluated. Research results: Atrial fibrillation was detected in 24.2% of patients. The highest prevalence was observed in patients with hyperthyroidism (37.5%), which was significantly higher than in patients without thyroid pathology (15.0%) (p<0.05). In hypothyroidism, AF was detected in 20.0% of cases. Paroxysmal AF predominated in hyperthyroidism (66.7%), whereas persistent AF was more common in hypothyroidism (62.5%). Conclusion: Thyroid pathology significantly influences the prevalence and clinical forms of atrial fibrillation in patients with IHD. Hyperthyroidism is associated with a higher prevalence and predominantly paroxysmal AF, while hypothyroidism is more often associated with persistent AF.
Key words
ischemic heart disease, atrial fibrillation, hyperthyroidism, hypothyroidism, arrhythmia
Literature
1. Biondi B., Cooper D.S. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews. 2008;29(1):76–131. 2. Camm A.J., Lip G.Y.H., De Caterina R. et al. 2016 ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2016;37(38):2893–2962. 3. Cappola A.R., Fried L.P., Arnold A.M. et al. Thyroid status and cardiovascular risk. JAMA. 2006;295(9):1033–1041. 4. Collet T.H., Gussekloo J., Bauer D.C. et al. Subclinical hyperthyroidism and risk of coronary heart disease. Archives of Internal Medicine. 2012;172(10):799–809. 5. Fazio S., Palmieri E.A., Lombardi G., Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Progress in Hormone Research. 2004;59:31–50. 6. Jabbar A., Pingitore A., Pearce S.H.S. et al. Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology. 2017;14:39–55. 7. January C.T., Wann L.S., Calkins H. et al. 2019 AHA/ACC/HRS guideline for atrial fibrillation. Circulation. 2019;140:e125– e151. 8. Klein I., Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725–1735. 9. Rodondi N., den Elzen W.P.J., Bauer D.C. et al. Subclinical hypothyroidism and coronary heart disease. JAMA. 2010;304(12):1365–1374. 10. Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin and risk of atrial fibrillation. New England Journal of Medicine. 1994; 331: 1249–1252. 11. Ярмухамедова С.Х., Амирова Ш.А (2025). Определение показателей диастолической дисфункции правого желудочка у больных с АГ. Science and Education, 4(5), 595-600.